Rodman & Renshaw analyst Elemer Piros initiated coverage of Mira Pharmaceuticals with a Buy rating and $17 price target. Mira is developing next-generation, orally available ketamine and medicinal marijuana derivatives, notes the analyst, whose Buy thesis is based on the firm’s view of the potential future cash flows from the company’s Ketamir-2 program and its assessment of the probability of its success.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRA:
- Mira Pharmaceuticals presents preclinical data for Ketamir-2
- Mira Pharmaceuticals advances Ketamir-2 development
- MIRA designates neuropathic pain as primary indication for Ketamir-2
- MIRA says it achieves 100% reversal of neuropathic pain with oral Ketamir-2
- Mira Pharmaceuticals provides update on preparing IND submission